Hemetron

What Hemetron does

Hemetron AG is a Swiss medical-device company founded in 2021 as an official spin-off of ETH Zürich, headquartered in Zürich, Switzerland. The company is developing a handheld at-home blood testing platform that quantitatively measures C-reactive protein (CRP), the most widely accepted inflammation marker, from a single finger-prick capillary blood sample. The core technology combines microfluidic sample processing on disposable test strips with integrated electrochemical detection, delivering results in approximately ten minutes without the need to ship samples to a centralized laboratory. A published clinical pilot study validates the device's accuracy against central-laboratory reference methods, and a companion smartphone application tracks results over time and supports sharing with healthcare professionals.

Hemetron serves two primary customer segments: private users with chronic inflammatory conditions (for example rheumatic diseases) who want frequent self-monitoring, and the healthcare professionals treating those patients who currently rely on centralized lab tests roughly every three to six months. The stated value proposition is to convert an infrequent, lab-bound measurement into daily-to-weekly home monitoring, enabling earlier detection of flare-ups and more responsive treatment titration. The company also positions a secondary B2B motion targeting clinics, clinical research, and population-health deployments.

The business model combines one-time hardware device sales with a recurring razor/blade revenue stream from single-use microfluidic test strips. Go-to-market is pre-launch: the company website directs prospects to Mailchimp email-capture forms segmented into private users, healthcare professionals, and business customers, with pre-orders not yet open. Hemetron is pre-revenue and operates with 1-10 employees, having secured roughly $2 million across multiple early-stage funding rounds (2020-2024), Innosuisse public funding support in 2025, and selection into the 2026 Sitem Startup Club MedTech Booster Program. Alexander Tanno is identified as Chief Executive Officer. No CE mark, FDA clearance, or formal regulatory certification is documented in the available sources.

Name

Hemetron

Legal name

Hemetron AG

Website

https://hemetron.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Hemetron AG is a Swiss ETH Zürich spin-off developing a handheld at-home blood testing device that quantitatively measures C-reactive protein (CRP) in about ten minutes from a finger-prick sample, serving patients with chronic inflammatory diseases and their physicians.

Ownership category

akta.pro rank

Product category

Point-of-Care Diagnostics

NAICS

Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK)

akta.pro secondary industries

Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE), Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL), Point-of-Care & Decentralized Trial Testing Services (HLAGAEAK)

Keywords

• At-home blood testing
• C-reactive protein monitoring
• Point-of-care diagnostics
• Microfluidic test strips
• Electrochemical biosensors

Headquarters

HQ city

Zürich

HQ country

Switzerland

HQ region

Europe

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Others

Revenue model

1. Hardware device sales: One-time sale of the at-home blood testing device to private users, healthcare professionals, and business customers. Pre-orders not yet open at time of source capture; revenue is pre-launch with email-list capture in place.
2. Consumable microfluidic test strips (recurring): Recurring revenue from single-use microfluidic test strips required for each measurement. Frequency of purchase scales with monitoring intensity (daily to weekly per user), creating an ongoing razor/blade stream on top of the hardware sale.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Core offering

Hemetron develops and is preparing to commercialize a handheld at-home blood testing device that quantitatively measures C-reactive protein (CRP) from a finger-prick capillary blood sample in approximately 10 minutes, using a disposable microfluidic test strip with integrated electrochemical sensors paired with a companion smartphone app. The device is aimed at patients with chronic inflammatory conditions (e.g., rheumatic diseases) and their treating physicians, replacing infrequent centralized lab testing (every 3–6 months) with frequent at-home monitoring. Revenue is expected from one-time hardware device sales plus recurring sales of single-use microfluidic test strips.

Product overview

Hemetron offers a single unified at-home blood testing product, built around one core device — the Hemetron at-home CRP blood test — which combines a disposable microfluidic test strip with integrated electrochemical sensors and is paired with a companion smartphone tracking app for data review. The platform is designed for unsupervised home use and delivers lab-grade quantitative C-reactive protein (CRP) results within roughly 10 minutes from a tiny capillary blood drop, with no sample shipping required. According to the company, the underlying detection platform is compatible with almost any blood test, and additional biomarkers are in planning, suggesting a future expansion of tests on the same core hardware/app architecture.

Differentiator

Problem solved

Functional benefit

Products and services

• Hemetron At-Home CRP Blood Test Handheld at-home blood testing device that quantitatively measures C-reactive protein (CRP), the most widely accepted inflammation marker, within approximately 10 minutes from a single drop of capillary blood without requiring sample shipping to a central lab. Designed for patients with chronic inflammatory diseases (e.g., rheumatic conditions) and the physicians who treat them.
• Hemetron Microfluidic Test Strip with Electrochemical Sensor Disposable single-use microfluidic test strip that automatically channels and prepares the finger-prick blood sample through microfluidic processing and delivers highly sensitive, quantitative CRP results via integrated electrochemical sensors. Functions as a recurring razor/blade consumable for the Hemetron device.
• Hemetron Smartphone Tracking App Companion smartphone application that allows users to track their blood values (CRP inflammation levels) over time, enabling continuous monitoring and remote sharing of results with healthcare professionals to support treatment optimization.

Quantifiable outcome

• Quantitative lab-grade CRP result in approximately 10 minutes from a finger-prick sample
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered flagship — parent academic institution / origin of the spin-off, core — flagship accelerator/program partnership, minor — research collaborator featured in supporters logos and minor — accelerator / ecosystem partner featured in supporters logos.

• ETH Zürichflagship — parent academic institution / origin of the spin-offStrategic or Co-development PartnerHemetron AG is described as an official spin-off of ETH Zürich, indicating origin from and ongoing institutional relationship with the university. ETH is featured in the collaborators/supporters logos on the contact page.
• Sitem Startup Clubcore — flagship accelerator/program partnershipStrategic or Co-development PartnerSelected for the 2026 Sitem Startup Club MedTech Booster Program, joining a cohort of eight startups from Switzerland, the United States, and Bosnia. The MedTech Booster Program supports MedTech founders with validation, mentorship, and ecosystem access.
• Botnar Research Centre for Child Health (BRCCH)minor — research collaborator featured in supporters logosStrategic or Co-development PartnerBRCCH is listed in the collaborators and supporters logos on the contact page, indicating a research / institutional relationship relevant to the development of the at-home blood testing platform.
• DayOneminor — accelerator / ecosystem partner featured in supporters logosStrategic or Co-development PartnerDayOne is listed in the collaborators and supporters logos on the contact page, indicating participation in the DayOne healthcare innovation accelerator/ecosystem in the Basel/Swiss region.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Emerging players

• Thriva: UK-based at-home blood testing service offering recurring finger-prick biomarker panels (including inflammation markers) with clinician review. Comparable as a recurring, finger-prick-based consumer inflammation testing brand targeting proactive health monitoring.

Direct peers

• Everlywell: Direct-to-consumer at-home diagnostic testing brand offering a range of blood-based biomarker tests shipped and analyzed at partner labs. Comparable in DTC motion and inflammation/health-monitoring use cases, though Everlywell relies on centralized lab analysis rather than Hemetron's at-home quantitative readout.
• Babson Diagnostics: Develops small-volume capillary blood diagnostics intended for accessible settings including retail and home-adjacent use. Comparable to Hemetron in targeting convenient, low-blood-volume, quantitative blood testing outside of traditional central labs.
• Healthy.io: Consumer smartphone-based diagnostics company offering at-home clinical-grade tests (initially urinalysis, expanding into chronic kidney disease). Comparable in the smartphone-paired, at-home clinical-grade testing model and DTC + B2B clinical GTM motion.
• Tasso Inc. Developer of patient-friendly capillary blood collection devices (Tasso OnDemand, Tasso SST) used for remote blood sampling. Comparable as a decentralized, patient-centric blood sampling/diagnostics platform, though Tasso primarily enables sample collection rather than integrated electrochemical readout.
• Cue Health: Consumer-grade at-home molecular and health diagnostics platform with connected hardware and disposable cartridges. Directly comparable to Hemetron in pursuing lab-grade, connected, cartridge-based diagnostics for home use, although Cue focuses on molecular targets rather than CRP protein biomarkers.

Broad incumbents

• Abbott (Diagnostics): Global diagnostics incumbent offering central-lab CRP testing (Architect/Alinity) and point-of-care platforms (i-STAT). Relevant incumbent for both hospital lab and clinical POC segments where Hemetron would compete, and a likely partner/acquirer for at-home distribution.
• Roche Diagnostics: World-leading in-vitro diagnostics company with cobas central-lab CRP assays and a broad chronic disease management portfolio. Comparable as a centralized CRP testing incumbent and as a strategic partner/acquirer for at-home chronic inflammatory disease monitoring.
• QuidelOrtho: Large diagnostics company with broad rapid and point-of-care CRP and inflammatory marker assays installed in clinics and hospitals. Comparable as a competing provider of quantitative CRP testing, and an obvious incumbent Hemetron would need to displace or differentiate against in clinical accounts.

Others

• DayOne (DayOne Accelerator): Swiss healthcare innovation accelerator based in Basel listed as a Hemetron collaborator/supporter. Relevant ecosystem participant rather than a competitor, but indicative of the Swiss digital-health network Hemetron is plugged into.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/hemetron
• Facebookfacebook.com/Hemetron
• LinkedInlinkedin.com/company/42766873

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds6 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hemetron